Japan Meningococcal Vaccines Market Size & Outlook
Japan meningococcal vaccines market, 2018-2030 (US$M)
Related Markets
Japan meningococcal vaccines market highlights
- The Japan meningococcal vaccines market generated a revenue of USD 51.0 million in 2021 and is expected to reach USD 118.8 million by 2030.
- The Japan market is expected to grow at a CAGR of 9.9% from 2022 to 2030.
- In terms of segment, quadrivalent was the largest revenue generating type in 2021.
- Quadrivalent is the most lucrative type segment registering the fastest growth during the forecast period.
Meningococcal vaccines market data book summary
| Market revenue in 2021 | USD 51.0 million |
| Market revenue in 2030 | USD 118.8 million |
| Growth rate | 9.9% (CAGR from 2021 to 2030) |
| Largest segment | Quadrivalent |
| Fastest growing segment | Quadrivalent |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bivalent, Quadrivalent |
| Key market players worldwide | Pfizer Inc, Sanofi SA, GSK PLC, Merck & Co Inc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology |
Other key industry trends
- In terms of revenue, Japan accounted for 1.8% of the global meningococcal vaccines market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China meningococcal vaccines market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 101.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Meningococcal Vaccines Market Scope
Meningococcal Vaccines Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan meningococcal vaccines market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to meningococcal vaccines market will help companies and investors design strategic landscapes.
Quadrivalent was the largest segment with a revenue share of 56.86% in 2021. Horizon Databook has segmented the Japan meningococcal vaccines market based on bivalent, quadrivalent covering the revenue growth of each sub-segment from 2018 to 2030.
In Japan, incidence rate of invasive meningococcal disease is around 0.028 cases per 100,000 population. Serogroup Y, C, and B are predominant bacterial variants; out of which, serogroup Y accounts for nearly 45% of total IMD cases.
Moreover, the National Epidemiological Surveillance on Infectious Disease (NESID) network in the country reported that serogroup B accounted for 20% of total IMD cases from January 2017 to June 2019. The Men ACWY conjugate vaccine has approval in Japan; however, it is not included in the National Immunization Program of the country.
Meningococcal vaccine was introduced as voluntary vaccine in Japan in 2015. The country does not offer this as a routine vaccination in children against either meningococcal B or C. It cost more than USD 220 for the vaccination against meningococcal infections.
Reasons to subscribe to Japan meningococcal vaccines market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan meningococcal vaccines market databook
-
Our clientele includes a mix of meningococcal vaccines market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan meningococcal vaccines market , including forecasts for subscribers. This country databook contains high-level insights into Japan meningococcal vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan meningococcal vaccines market size, by type, 2018-2030 (US$M)
Japan Meningococcal Vaccines Market Outlook Share, 2021 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
